Colgate-Palmolive (NYSE: CL) delivered a Q2 beat that was less about the quarter itself and more about what it unlocked for the rest of the year. Base Business EPS of $0.99 topped the $0.95 consensus by 4.4%. The real signal, however, came in the guidance revision. Management now expects full-year gross profit margin to be roughly flat versus the prior 'down' outlook, and lifted Base Business EPS growth to mid-single-digits from low-to-mid. That's a meaningful upgrade for a consumer staple navigating a volatile cost environment.
Net sales rose 4.9% to $5.36B, modestly ahead of the $5.36B estimate, with organic sales up 2.4%. The organic figure included a 0.4% drag from the exit of private label pet food, so underlying demand was a touch stronger than the headline suggests. Latin America led with 5.3% organic growth. North America posted a 3.0% organic decline driven by a 3.9% volume drop. Hill's Pet Nutrition grew organic sales 2.1% on pricing of 3.9%, offsetting a 1.8% volume decline.
The gross margin story is the quarter's most important development. Gross profit margin expanded 140 basis points to 61.5% on both a GAAP and Base Business basis. This is a sharp reversal from the compression many consumer companies have reported, and it's what gave management the confidence to upgrade the full-year margin outlook. The improvement came despite a 15% surge in advertising investment to $777M. It suggests Colgate's cost structure is benefiting from its Strategic Growth and Productivity Program even as it spends aggressively on brand building.
GAAP operating profit fell 6% to $1.02B. That's entirely a function of $129M in restructuring charges from the productivity program. Strip those out, and Base Business operating profit rose 5% to $1.145B, with operating margin expanding 10 basis points to 21.4%. The gap between GAAP and Base Business results is widening as the restructuring program accelerates, which makes the non-GAAP figures the more relevant measure for underlying performance.
Advertising spending at 14.5% of sales is running well above historical levels. Management explicitly committed to 'strong levels of investment' continuing in the back half. This is part of its 2030 strategy focused on premium innovation and omni-channel demand generation. It's a deliberate trade-off: near-term margin expansion is being partially reinvested into top-line growth drivers. The 15% ad increase in Q2 is the largest quarterly jump in recent memory, and it's funding share stability. Global toothpaste market share held at 41.3% and manual toothbrush share at 32.7% year to date, reinforcing category leadership.
The guidance upgrade is modest in magnitude but significant in direction. Raising gross margin from 'down' to 'roughly flat' implies management sees enough cost improvement and pricing power to offset inflation. The EPS growth upgrade to mid-single-digits from low-to-mid is a 100-200 basis point improvement at the midpoint. Net sales and organic sales guidance were reiterated at +2-6% and +1-4% respectively. The top-line trajectory hasn't changed, but the profit conversion is improving.
The forward question is whether the margin improvement is structural or cyclical. The 140bps gross margin expansion in Q2 came despite a difficult operating environment, which points to structural benefits from the productivity program. But the back half will face tougher comparisons as prior-year pricing actions anniversary. If Colgate can hold gross margins near 61% while sustaining elevated advertising, the mid-single-digit EPS growth guide may prove conservative.